Labway, Inc. 上海兰卫 has been providing professional testing services and healthcare management for healthcare institutions for over 22 years, evolving into a group enterprise with more than 1 billion RMB annual sales. The company's core competence lies in strategic alliances, optimized operation management, and intensive operation. Labway has introduced the Regional Medical Laboratory Net model, partnering with regional healthcare reforms in China, operating in 8 regional independent laboratory centers across 6 provinces and municipalities with 10 more in progress. Their certifications include ISO15189, CAP, and CMA, and they have been recognized as a National High-tech Enterprise, Shanghai Scientific Giant Developing Enterprise, and Enterprise Technology Center. Labway has established successful partnerships with global medical device and diagnostic companies such as Roche, Sysmex, bioMerieux, BD, and Dako. The last investment of CNY533.00MPost-IPO equity investment was made on 15 March 2017 by Heilan Group. This signifies Labway's potential for growth and impact in the healthcare industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | CNY533.00M | 1 | Heilan Group | 15 Mar 2017 |
| Post-IPO Equity | CNY170.00M | 2 | Tianxun Capital, Hepalink | 04 Jul 2016 |
| Post-IPO Equity | CNY54.00M | 7 |
|
24 Feb 2016 |
No recent news or press coverage available for Labway, Inc. 上海兰卫.
We care about your data, and we'd love to use cookies make your experience better.